Oligonucleotide-based Therapies Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Antisense, Ribozymes, Aptamers, Mirna, CPG/Immunostimulatory, RNAi.); Application (Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Others.) and Geography

Report Code: TIPRE00022877 | No. of Pages: 150 | Category: Biotechnology | Status: Upcoming

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET OVERVIEW

Oligonucleotides are short chain RNA or DNA typically made by using automated synthesizers. Oligonucleotides therapy is different from conventional medicine since it can inhibit the expression of specific genes and their development takes place with the raw chemical modified artificial nucleus acids. This lead to development of brand new oligonucleotides targeting certain genes and treating chronic diseases. They are broadly used in applications such as infectious diseases, oncology, kidney diseases, and cardiovascular diseases.

MARKET SCOPE

The "Global Oligonucleotide-Based Therapies Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the oligonucleotide-based therapies market with detailed market segmentation by type, application, and geography. The report provides key statistics on the market status of the leading oligonucleotide-based therapies market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

  •  Based on type, the global oligonucleotide-based therapies market is segmented into antisense, ribozymes, aptamers, miRNA, CpG/Immunostimulatory and RNAi.
  •  On the basis of application, the market is bifurcated into infectious diseases, oncology, neurodegenerative disorders, cardiovascular diseases, kidney diseases and others.

MARKET DYNAMICS
Drivers

  •  Increasing incidence of cancer and infectious disease and the necessity for personalized medicines for neurodegenerative disorders is expected to drive the oligonucleotide-based therapies market.
  •  Increasing demand for novel therapies and growing innovative new oligonucleotides boosts the market growth.
  •  Rising licensing and collaboration activities and growing demand for advanced technologies in oligonucleotide therapeutics fuel the market growth.

Restraints

  •  The incapability to detect minor antibodies.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The oligonucleotide-based therapies market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the oligonucleotide-based therapies market in these regions.

IMPACT OF COVID-19 ON OLIGONUCLEOTIDE-BASED THERAPIES MARKET
COVID-19 first began in Wuhan (China) during December 2019, and since then, it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, UK, Turkey, Italy, and Spain are some of the worst affected countries in terms of confirmed cases and reported deaths. With the outbreak of pandemic, a slight decrease in the oligonucleotide-based drugs sales was seen due to worldwide restrictions and lockdown imposed during the COVID-19 pandemic. However, the pharmaceutical and biopharmaceutical companies, along with the players of the oligonucleotide market, came forward to contribute to research efforts worldwide by providing oligo products. These products were used for development of test kits, treatments, and vaccines that target the novel coronavirus infection. The various initiatives by the market players and usage of a wide range of oligonucleotide products like probes and primers in coronavirus research has helped researchers gain a better insight of the virus. Hence, the oligonucleotide market is estimated to witness growth in coming years.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the oligonucleotide-based therapies market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market players from oligonucleotide-based therapies market are anticipated to have lucrative growth opportunities in the future with the rising demand for oligonucleotide-based therapies in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the oligonucleotide-based therapies market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

  •  PCI Biotech
  •  SomaGenics
  •  InteRNA Technologies
  •  Frontiers
  •  miRagen Therapeutics, Inc.
  •  Ionis Pharmaceuticals, Inc.
  •  Aligos Therapeutics
  •  Gilead Sciences, Inc.
  •  Biogen Inc.
  •  Regulus Therapeutics Inc.

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Oligonucleotide-based Therapies Market - By Type
1.3.2 Oligonucleotide-based Therapies Market - By Application
1.3.3 Oligonucleotide-based Therapies Market - By Region
1.3.3.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. OLIGONUCLEOTIDE-BASED THERAPIES MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1 Bargaining Power of Buyers
4.2.1 Bargaining Power of Suppliers
4.2.1 Threat of Substitute
4.2.1 Threat of New Entrants
4.2.1 Competitive Rivalry
4.3. EXPERT OPINIONS

5. OLIGONUCLEOTIDE-BASED THERAPIES MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

6. OLIGONUCLEOTIDE-BASED THERAPIES MARKET - GLOBAL MARKET ANALYSIS
6.1. OLIGONUCLEOTIDE-BASED THERAPIES - GLOBAL MARKET OVERVIEW
6.2. OLIGONUCLEOTIDE-BASED THERAPIES - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE

7. OLIGONUCLEOTIDE-BASED THERAPIES MARKET - REVENUE AND FORECASTS TO 2028 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. ANTISENSE
7.3.1. Overview
7.3.2. Antisense Market Forecast and Analysis
7.4. RIBOZYMES
7.4.1. Overview
7.4.2. Ribozymes Market Forecast and Analysis
7.5. APTAMERS
7.5.1. Overview
7.5.2. Aptamers Market Forecast and Analysis
7.6. MIRNA
7.6.1. Overview
7.6.2. Mirna Market Forecast and Analysis
7.7. CPG/IMMUNOSTIMULATORY
7.7.1. Overview
7.7.2. CPG/Immunostimulatory Market Forecast and Analysis
7.8. RNAI.
7.8.1. Overview
7.8.2. RNAi. Market Forecast and Analysis
8. OLIGONUCLEOTIDE-BASED THERAPIES MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. INFECTIOUS DISEASES
8.3.1. Overview
8.3.2. Infectious Diseases Market Forecast and Analysis
8.4. ONCOLOGY
8.4.1. Overview
8.4.2. Oncology Market Forecast and Analysis
8.5. NEURODEGENERATIVE DISORDERS
8.5.1. Overview
8.5.2. Neurodegenerative Disorders Market Forecast and Analysis
8.6. CARDIOVASCULAR DISEASES
8.6.1. Overview
8.6.2. Cardiovascular Diseases Market Forecast and Analysis
8.7. KIDNEY DISEASES
8.7.1. Overview
8.7.2. Kidney Diseases Market Forecast and Analysis
8.8. OTHERS.
8.8.1. Overview
8.8.2. Others. Market Forecast and Analysis

9. OLIGONUCLEOTIDE-BASED THERAPIES MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Oligonucleotide-based Therapies Market Overview
9.1.2 North America Oligonucleotide-based Therapies Market Forecasts and Analysis
9.1.3 North America Oligonucleotide-based Therapies Market Forecasts and Analysis - By Type
9.1.4 North America Oligonucleotide-based Therapies Market Forecasts and Analysis - By Application
9.1.5 North America Oligonucleotide-based Therapies Market Forecasts and Analysis - By Countries
9.1.5.1 Canada Oligonucleotide-based Therapies Market
9.1.5.1.1 Canada Oligonucleotide-based Therapies Market by Type
9.1.5.1.2 Canada Oligonucleotide-based Therapies Market by Application
9.1.5.2 Mexico Oligonucleotide-based Therapies Market
9.1.5.2.1 Mexico Oligonucleotide-based Therapies Market by Type
9.1.5.2.2 Mexico Oligonucleotide-based Therapies Market by Application
9.1.5.3 US Oligonucleotide-based Therapies Market
9.1.5.3.1 US Oligonucleotide-based Therapies Market by Type
9.1.5.3.2 US Oligonucleotide-based Therapies Market by Application
9.2. EUROPE
9.2.1 Europe Oligonucleotide-based Therapies Market Overview
9.2.2 Europe Oligonucleotide-based Therapies Market Forecasts and Analysis
9.2.3 Europe Oligonucleotide-based Therapies Market Forecasts and Analysis - By Type
9.2.4 Europe Oligonucleotide-based Therapies Market Forecasts and Analysis - By Application
9.2.5 Europe Oligonucleotide-based Therapies Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Oligonucleotide-based Therapies Market
9.2.5.1.1 Germany Oligonucleotide-based Therapies Market by Type
9.2.5.1.2 Germany Oligonucleotide-based Therapies Market by Application
9.2.5.2 France Oligonucleotide-based Therapies Market
9.2.5.2.1 France Oligonucleotide-based Therapies Market by Type
9.2.5.2.2 France Oligonucleotide-based Therapies Market by Application
9.2.5.3 Italy Oligonucleotide-based Therapies Market
9.2.5.3.1 Italy Oligonucleotide-based Therapies Market by Type
9.2.5.3.2 Italy Oligonucleotide-based Therapies Market by Application
9.2.5.4 Spain Oligonucleotide-based Therapies Market
9.2.5.4.1 Spain Oligonucleotide-based Therapies Market by Type
9.2.5.4.2 Spain Oligonucleotide-based Therapies Market by Application
9.2.5.5 United Kingdom Oligonucleotide-based Therapies Market
9.2.5.5.1 United Kingdom Oligonucleotide-based Therapies Market by Type
9.2.5.5.2 United Kingdom Oligonucleotide-based Therapies Market by Application
9.2.5.6 Rest of Europe Oligonucleotide-based Therapies Market
9.2.5.6.1 Rest of Europe Oligonucleotide-based Therapies Market by Type
9.2.5.6.2 Rest of Europe Oligonucleotide-based Therapies Market by Application
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Oligonucleotide-based Therapies Market Overview
9.3.2 Asia-Pacific Oligonucleotide-based Therapies Market Forecasts and Analysis
9.3.3 Asia-Pacific Oligonucleotide-based Therapies Market Forecasts and Analysis - By Type
9.3.4 Asia-Pacific Oligonucleotide-based Therapies Market Forecasts and Analysis - By Application
9.3.5 Asia-Pacific Oligonucleotide-based Therapies Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Oligonucleotide-based Therapies Market
9.3.5.1.1 Australia Oligonucleotide-based Therapies Market by Type
9.3.5.1.2 Australia Oligonucleotide-based Therapies Market by Application
9.3.5.2 China Oligonucleotide-based Therapies Market
9.3.5.2.1 China Oligonucleotide-based Therapies Market by Type
9.3.5.2.2 China Oligonucleotide-based Therapies Market by Application
9.3.5.3 India Oligonucleotide-based Therapies Market
9.3.5.3.1 India Oligonucleotide-based Therapies Market by Type
9.3.5.3.2 India Oligonucleotide-based Therapies Market by Application
9.3.5.4 Japan Oligonucleotide-based Therapies Market
9.3.5.4.1 Japan Oligonucleotide-based Therapies Market by Type
9.3.5.4.2 Japan Oligonucleotide-based Therapies Market by Application
9.3.5.5 South Korea Oligonucleotide-based Therapies Market
9.3.5.5.1 South Korea Oligonucleotide-based Therapies Market by Type
9.3.5.5.2 South Korea Oligonucleotide-based Therapies Market by Application
9.3.5.6 Rest of Asia-Pacific Oligonucleotide-based Therapies Market
9.3.5.6.1 Rest of Asia-Pacific Oligonucleotide-based Therapies Market by Type
9.3.5.6.2 Rest of Asia-Pacific Oligonucleotide-based Therapies Market by Application
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Oligonucleotide-based Therapies Market Overview
9.4.2 Middle East and Africa Oligonucleotide-based Therapies Market Forecasts and Analysis
9.4.3 Middle East and Africa Oligonucleotide-based Therapies Market Forecasts and Analysis - By Type
9.4.4 Middle East and Africa Oligonucleotide-based Therapies Market Forecasts and Analysis - By Application
9.4.5 Middle East and Africa Oligonucleotide-based Therapies Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Oligonucleotide-based Therapies Market
9.4.5.1.1 South Africa Oligonucleotide-based Therapies Market by Type
9.4.5.1.2 South Africa Oligonucleotide-based Therapies Market by Application
9.4.5.2 Saudi Arabia Oligonucleotide-based Therapies Market
9.4.5.2.1 Saudi Arabia Oligonucleotide-based Therapies Market by Type
9.4.5.2.2 Saudi Arabia Oligonucleotide-based Therapies Market by Application
9.4.5.3 U.A.E Oligonucleotide-based Therapies Market
9.4.5.3.1 U.A.E Oligonucleotide-based Therapies Market by Type
9.4.5.3.2 U.A.E Oligonucleotide-based Therapies Market by Application
9.4.5.4 Rest of Middle East and Africa Oligonucleotide-based Therapies Market
9.4.5.4.1 Rest of Middle East and Africa Oligonucleotide-based Therapies Market by Type
9.4.5.4.2 Rest of Middle East and Africa Oligonucleotide-based Therapies Market by Application
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Oligonucleotide-based Therapies Market Overview
9.5.2 South and Central America Oligonucleotide-based Therapies Market Forecasts and Analysis
9.5.3 South and Central America Oligonucleotide-based Therapies Market Forecasts and Analysis - By Type
9.5.4 South and Central America Oligonucleotide-based Therapies Market Forecasts and Analysis - By Application
9.5.5 South and Central America Oligonucleotide-based Therapies Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Oligonucleotide-based Therapies Market
9.5.5.1.1 Brazil Oligonucleotide-based Therapies Market by Type
9.5.5.1.2 Brazil Oligonucleotide-based Therapies Market by Application
9.5.5.2 Argentina Oligonucleotide-based Therapies Market
9.5.5.2.1 Argentina Oligonucleotide-based Therapies Market by Type
9.5.5.2.2 Argentina Oligonucleotide-based Therapies Market by Application
9.5.5.3 Rest of South and Central America Oligonucleotide-based Therapies Market
9.5.5.3.1 Rest of South and Central America Oligonucleotide-based Therapies Market by Type
9.5.5.3.2 Rest of South and Central America Oligonucleotide-based Therapies Market by Application

10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

11. OLIGONUCLEOTIDE-BASED THERAPIES MARKET, KEY COMPANY PROFILES
11.1. PCI BIOTECH
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. SOMAGENICS
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. INTERNA TECHNOLOGIES
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. FRONTIERS
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. MIRAGEN THERAPEUTICS, INC.
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. IONIS PHARMACEUTICALS, INC.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. ALIGOS THERAPEUTICS
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. GILEAD SCIENCES, INC.
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. BIOGEN INC.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. REGULUS THERAPEUTICS INC.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments

12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

1. PCI Biotech
2. SomaGenics
3. InteRNA Technologies
4. Frontiers
5. miRagen Therapeutics, Inc.
6. Ionis Pharmaceuticals, Inc.
7. Aligos Therapeutics
8. Gilead Sciences, Inc.
9. Biogen Inc.
10. Regulus Therapeutics Inc.
TIPRE00022877
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking